Moleculin Biotech Inc (MBRX): In at 20k shares $1.49

S&P 500

US TECH 100

Dow Jones

Brent Oil

Bitcoin

Moleculin Biotech Inc (MBRX)

Reply Private New

Keep Last Read

Next 10 Prev Next

Send PM Follow Ignore

Followers	2
Posts	453
Boards Moderated	0
Alias Born	10/07/2017

Re: None

Thursday, 04/25/2019 8:04:14 AM

Thursday, April 25, 2019 8:04:14 AM

In at 20k shares $1.49

Keep Last Read

Next 10 Prev Next

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:

1D
1M
3M
6M
1Y
5Y

Detailed Quote

Recent MBRX News

Form 8-K - Current report • Edgar (US Regulatory) • 08/01/2024 12:35:16 PM
Form 8-K - Current report • Edgar (US Regulatory) • 08/01/2024 12:30:17 PM
Moleculin Announces Plans for MIRACLE Phase 3 Pivotal Trial • PR Newswire (US) • 08/01/2024 12:30:00 PM
Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 07/30/2024 11:00:46 AM
Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 07/22/2024 09:31:38 PM
Form 8-K - Current report • Edgar (US Regulatory) • 07/10/2024 12:30:31 PM
Moleculin Completes End of Phase 2 Meeting with FDA for Annamycin in AML • PR Newswire (US) • 07/10/2024 12:30:00 PM
Form 8-K - Current report • Edgar (US Regulatory) • 06/18/2024 09:00:44 PM
Form 8-K - Current report • Edgar (US Regulatory) • 06/14/2024 12:00:40 PM
Moleculin Announces Additional Positive Preliminary Interim Data from AML Clinical Trial • PR Newswire (US) • 06/14/2024 12:00:00 PM
Moleculin to Present at the Virtual Investor Pitch Conference • PR Newswire (US) • 06/12/2024 01:00:00 PM
Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 06/07/2024 09:05:48 PM
Moleculin to Participate in the Virtual Investor Lunch Break Series • PR Newswire (US) • 06/05/2024 12:55:00 PM
Form 8-K - Current report • Edgar (US Regulatory) • 05/16/2024 12:32:14 PM
Moleculin Abstract Accepted for Poster Presentation at the European Hematology Association (EHA) 2024 Hybrid Congress • PR Newswire (US) • 05/16/2024 12:32:00 PM
Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2024 12:38:16 PM
Moleculin Announces Commencement of NIH-Funded Phase 2 Clinical Trial of STAT3 Inhibitor for the Treatment of Glioblastoma (NU 21C06) • PR Newswire (US) • 05/15/2024 12:38:00 PM
Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2024 08:16:53 PM
Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 05/13/2024 02:53:22 PM
Form 8-K - Current report • Edgar (US Regulatory) • 05/13/2024 11:30:14 AM
Moleculin Reports First Quarter 2024 Financial Results and Provides Corporate Update • PR Newswire (US) • 05/13/2024 11:30:00 AM
Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 08:30:38 PM
Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 12:30:13 PM
Moleculin Announces U.S. Patent Issue Notification for Lipid-Based Delivery Technology for Annamycin • PR Newswire (US) • 05/09/2024 12:30:00 PM
Moleculin to Report First Quarter 2024 Financial Results on May 10, 2024 and Host Conference Call and Webcast • PR Newswire (US) • 05/08/2024 12:45:00 PM

More MBRX News

InvestorsHub NewsWire

FEATURED POET and Luxshare Tech Expand Product Offerings for Artificial Intelligence Networks • Aug 1, 2024 9:28 AM

Management Discusses Financial Filings of Global Arena Holding Inc., for 10-K 2023 and 10-Q, 1st Quarter 2024 • GAHC • Aug 1, 2024 9:14 AM

VAYK Announces LOI to Acquire $1 Million Home Service Company to Support Airbnb Business • VAYK • Aug 1, 2024 9:00 AM

Duane Forrester Joins INDEXR as SVP of Search • MONI • Jul 31, 2024 11:46 AM

Lingerie Fighting Championships Help Fulfill Death-Bed Promise With First Major Motion Picture • BOTY • Jul 31, 2024 9:00 AM

Kona Gold Beverage Significantly Reduces Debt from Multiple Holders • KGKG • Jul 31, 2024 9:00 AM

Start posting your company's news

Only $200 per official company press release!

InvestorsHub community

Register for free to join our community of investors and share your ideas

You'll also get access to streaming quotes, interactive charts, trades, portfolio, live options flow